Skip to main content Back to Top
Advertisement

CMS and Scope of Practice – Decoding CMS’s Deregulatory Efforts

 

Subscribe on iTune PodcastsListen on Google PlaySubscribe to Stitcher Podcasts Listen on Spotify Subscribe to TuneIn PodcastsSubscribe to iHeartRadio

Questions about what CMS’s recent comment request on removing barriers to clinicians practicing at the top of their license means for you? We’ve got answers! We’ll talk through CMS’s goals for scope of practice deregulation, ASHP’s advocacy efforts in response to the CMS comment request, the potential outcomes of these efforts, and our next steps to advance pharmacists’ scope of practice.



SPEAKERS

Tom KrausTom Kraus is Vice President for Government Relations at ASHP. He is a graduate of University of Michigan (BS Biology), Georgetown University Law Center (Doctor Of Law), and The Johns Hopkins University (MHS, Health Policy).



Jillanne Schulte WallJillanne Schulte Wall is the Senior Director of Health & Regulatory Policy for the American Society of Health-System Pharmacists (ASHP) in Bethesda, MD. She serves as ASHP’s primary liaison to federal regulatory agencies and, in conjunction with other members of the Government Relations team, develops and communicates of ASHP’s positions on federal and state laws, regulations, and guidance related to the profession of pharmacy. Additionally, Jillanne works closely with stakeholders in pharmacy, medicine, manufacturing, and patient advocacy on legislative and regulatory issues of importance to ASHP members. Prior to joining ASHP, Jillanne was the Director of Regulatory Affairs for the American Pharmacists Association in Washington, D.C. She began her career as a healthcare attorney at Feldesman Tucker Leifer Fidell LLP in Washington, DC, where she advised healthcare clients on corporate, regulatory, and transactional issues, with a particular emphasis on optimizing performance after the implementation of the Affordable Care Act.





The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.